1315 Capital Invests in Triple Ring Technologies
February 1, 2024
1315 Capital, a Philadelphia-based healthcare growth equity firm, made a growth capital investment in Triple Ring Technologies, a Silicon Valley-based medical device and life sciences co-development and engineering services company. The investment will accelerate Triple Ring's geographic expansion and extension of its R&D and product development services to scale its engineering and outsourced R&D services platform.
- Buyers
- 1315 Capital
- Targets
- Triple Ring Technologies
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
1315 Capital Invests in Primrose Bio
June 17, 2024
Biotechnology
1315 Capital, a Philadelphia-based healthcare-focused growth equity firm, made a significant equity investment in Primrose Bio to support development and commercial expansion of Primrose’s nucleic acid and protein manufacturing technologies. The funding will accelerate commercialization of the company’s Prima RNApols, Pfenex expression system, and PeliCRM carrier protein for therapeutics and vaccines.
-
Edison Partners Leads $5M Growth Investment in Ringmaster Technologies
January 14, 2020
Healthcare Services
Edison Partners led a $5 million growth investment in Ringmaster Technologies to help the healthcare workflow optimization company scale its cloud solutions and build its go-to-market engine. The funding will accelerate development of Ringmaster's automated workflow, quoting and administration platform for brokers, agencies, third-party administrators, MGUs and carriers in the stop-loss insurance market.
-
1315 Capital Backs USpharma Ltd. with Growth Equity Investment
June 30, 2025
Pharmaceuticals
USpharma Ltd., a Miami Lakes-based pharmaceutical development and manufacturing company, received a growth equity investment from Philadelphia-based 1315 Capital. The capital will be used to accelerate development and commercialization of USpharma’s pipeline, expand commercial reach, and scale operations at its 150,000 sq. ft. US-based GMP facility.
-
1315 Capital Provides Growth Financing to ProSciento
September 10, 2020
Healthcare Services
ProSciento, a San Diego–based specialty clinical research organization focused on NASH, diabetes and obesity, closed a growth financing round with healthcare investor 1315 Capital. The capital will support expansion of ProSciento's CRO operations and growth of its patient access solutions, including the NASH PASS registry.
-
1315 Capital Leads Growth Investment in Experic
October 29, 2024
Pharmaceuticals
Experic, a Cranbury, New Jersey-based CDMO and clinical trial supply services firm, received a growth capital investment led by 1315 Capital with participation from existing investors East Seattle Partners, Harro Höfliger Packaging Systems, Inc., and Kineticos Ventures. The capital will be used to enhance Experic’s manufacturing capabilities and accelerate its international expansion to better serve biopharmaceutical clients.
-
1315 Capital and John Martin Invest in Innovative ECMO Concepts
October 4, 2022
Healthcare Services
Innovative ECMO Concepts received a growth capital investment from 1315 Capital and John Martin, who was also named CEO. The funding will support expansion of the company's ECMO staffing, on-demand training, and patient transport services to increase ECMO capacity at hospitals and broaden access to ECLS.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.